A number of other analysts also recently weighed in on the company. Wells Fargo & Company reiterated an overweight rating on shares of Affimed in a research report on Thursday, August 18th. Stifel Nicolaus downgraded Affimed from a buy rating to a hold rating and dropped their price objective for the stock from $9.00 to $2.00 in a research report on Monday, October 10th. Finally, Cantor Fitzgerald reaffirmed an overweight rating on shares of Affimed in a report on Wednesday, September 21st. Two analysts have rated the stock with a hold rating and four have given a buy rating to the company. According to MarketBeat, the stock presently has an average rating of Moderate Buy and an average price target of $7.50.
Affimed Stock Down 1.4 %
AFMD stock opened at $2.11 on Monday. The business’s 50 day simple moving average is $1.93 and its 200 day simple moving average is $2.58. The firm has a market capitalization of $260.42 million, a PE ratio of -3.35 and a beta of 2.19. Affimed has a 1-year low of $1.40 and a 1-year high of $7.13. The company has a current ratio of 5.65, a quick ratio of 5.63 and a debt-to-equity ratio of 0.07.
Institutional Trading of Affimed
Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Germany, and rest of Europe. Its lead product candidate is AFM13, which has completed Phase II clinical study for peripheral T-cell lymphoma; in Phase IIa clinical trial for CD30-positive lymphoma; and in Phase I clinical trial for hodgkin lymphoma.
- Get a free copy of the StockNews.com research report on Affimed (AFMD)
- Is the 60/40 Portfolio Mix Still in Vogue?
- Salesforce Cuts Labor, Shows Strong Earnings Despite Challenges
- Microsoft Shares: Is it Time to Back Up the Truck?
- Three CBD Stocks to Dominate a Budding Industry
- Institutional Support for Analog Devices Remains High
Receive News & Ratings for Affimed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Affimed and related companies with MarketBeat.com's FREE daily email newsletter.